Switch theme
Sign up to access all valuation multiples
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
2001
141
LTM Revenue $93.9M
Last FY EBITDA -$1.9M
$281M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sanara MedTech has a last 12-month revenue (LTM) of $93.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sanara MedTech achieved revenue of $86.7M and an EBITDA of -$1.9M.
Sanara MedTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sanara MedTech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $93.9M | XXX | $86.7M | XXX | XXX | XXX |
| Gross Profit | $85.5M | XXX | $78.5M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$1.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2% | XXX | XXX | XXX |
| EBIT | -$7.1M | XXX | -$8.7M | XXX | XXX | XXX |
| EBIT Margin | -8% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$11.4M | XXX | -$9.7M | XXX | XXX | XXX |
| Net Margin | -12% | XXX | -11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sanara MedTech's stock price is $29.
Sanara MedTech has current market cap of $257M, and EV of $281M.
See Sanara MedTech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $281M | $257M | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sanara MedTech has market cap of $257M and EV of $281M.
Sanara MedTech's trades at 3.2x EV/Revenue multiple, and -151.2x EV/EBITDA.
Equity research analysts estimate Sanara MedTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sanara MedTech has a P/E ratio of -22.5x.
See valuation multiples for Sanara MedTech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $257M | XXX | $257M | XXX | XXX | XXX |
| EV (current) | $281M | XXX | $281M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -151.2x | XXX | XXX | XXX |
| EV/EBIT | -39.9x | XXX | -32.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -22.5x | XXX | -26.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1111.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanara MedTech's last 12 month revenue growth is 17%
Sanara MedTech's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.6M for the same period.
Sanara MedTech's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sanara MedTech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sanara MedTech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 101% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanara MedTech acquired XXX companies to date.
Last acquisition by Sanara MedTech was XXXXXXXX, XXXXX XXXXX XXXXXX . Sanara MedTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sanara MedTech founded? | Sanara MedTech was founded in 2001. |
| Where is Sanara MedTech headquartered? | Sanara MedTech is headquartered in United States of America. |
| How many employees does Sanara MedTech have? | As of today, Sanara MedTech has 141 employees. |
| Who is the CEO of Sanara MedTech? | Sanara MedTech's CEO is Mr. Ronald T. Nixon. |
| Is Sanara MedTech publicy listed? | Yes, Sanara MedTech is a public company listed on NAS. |
| What is the stock symbol of Sanara MedTech? | Sanara MedTech trades under SMTI ticker. |
| When did Sanara MedTech go public? | Sanara MedTech went public in 2020. |
| Who are competitors of Sanara MedTech? | Similar companies to Sanara MedTech include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sanara MedTech? | Sanara MedTech's current market cap is $257M |
| What is the current revenue of Sanara MedTech? | Sanara MedTech's last 12 months revenue is $93.9M. |
| What is the current revenue growth of Sanara MedTech? | Sanara MedTech revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Sanara MedTech? | Current revenue multiple of Sanara MedTech is 3.0x. |
| Is Sanara MedTech profitable? | Yes, Sanara MedTech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
